Posts

Posted on

Rocket Lab Closes Acquisition of Geost, Expanding Its National Security Capabilities with Launch, Spacecraft, and Now Payloads

Rocket Lab Closes Acquisition of Geost, Expanding Its National Security Capabilities with Launch, Spacecraft, and Now Payloads

The acquisition expands Rocket Lab’s end-to-end mission solutions with advanced electro-optical and infrared payloads for missile warning, tracking, and space domain awareness.

LONG BEACH, Calif.–(BUSINESS WIRE)–
Rocket Lab Corporation (Nasdaq: RKLB) (“Rocket Lab” or the “Company”), a global leader in launch services and space systems, today announced it has completed the acquisition of the parent holding company of Geost, LLC (“Geost”), a leading developer of electro-optical and infrared (EO/IR) sensor systems for national security space missions, from Lightridge Solutions, a portfolio company of ATL Partners. The acquisition, first announced on May 27, 2025, was completed for $275 million before closing adjustments, comprising approximately $125 million in cash and 3,057,588 shares of Rocket Lab common stock, with an additional potential earnout of up to $50 million tied to future revenue targets of Geost’s business.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250811878199/en/

Credit: Rocket Lab

Credit: Rocket Lab

With the closing of the transaction, Rocket Lab secures its status as a disruptive prime contractor for next-generation defense initiatives like the Golden Dome for America concept, and the Space Development Agency’s Proliferated Warfighter Space Architecture, adding Optical Systems to its portfolio of capabilities as a provider of complete, mission-ready spacecraft for U.S. national security programs.

Geost’s EO/IR technologies support missile warning and tracking, tactical intelligence, surveillance, reconnaissance, Earth observation, and space domain awareness, core capabilities critical to U.S. space assets operating in increasingly contested environments. Founded in 2004, Geost brings a proven record of performance across classified and unclassified missions, supplying resilient payloads that enhance national security and space situational awareness. In combining with Rocket Lab, Geost will tap into the Company’s resources and manufacturing expertise to boost high-volume production, making EO/IR technologies available at scale.

Rocket Lab founder and CEO, Sir Peter Beck, says: “Being able to quickly build and deploy entire satellite systems is the cornerstone of future U.S. defense strategy, and with this acquisition, we’re accelerating the delivery of mission critical payloads that support U.S. national security projects. This acquisition strengthens our role in building the resilient, responsive space architecture envisioned under Golden Dome, combining Geost’s proven sensing technologies with Rocket Lab’s ability to scale fast, secure, and integrated space solutions.”

Bill Gattle, CEO of Lightridge Solutions, adds: “This is a pivotal next step for Geost. Becoming part of Rocket Lab enables Geost to take its sensing technologies further, faster—joining forces with a company that’s redefining space system delivery. Geost is excited to partner with a team that shares a commitment to speed, innovation, and national purpose. Together, Geost and Rocket Lab can scale production, accelerate delivery, and strengthen the critical space capabilities our nation depends on.”

Geost will continue to operate in Arizona and Virginia, expanding Rocket Lab’s footprint across North America. In acquiring Geost, Rocket Lab will gain the company’s extensive product assets and manufacturing facilities and laboratories, intellectual property, and product inventory.

+ About Rocket Lab

Founded in 2006, Rocket Lab is an end-to-end space company with an established track record of mission success. We deliver reliable launch services, satellite manufacture, spacecraft components, and on-orbit management solutions that make it faster, easier, and more affordable to access space. Headquartered in Long Beach, California, Rocket Lab designs and manufactures the Electron small orbital launch vehicle, the HASTE suborbital launch vehicle for hypersonic tests, a family of flight proven spacecraft, and the larger Neutron launch vehicle for constellation deployment. Since its first orbital launch in January 2018, Rocket Lab’s Electron launch vehicle has become the second most frequently launched U.S. rocket annually. Rocket Lab has deployed 200+ payloads from its launch sites in the United States and New Zealand for private and public sector organizations, enabling operations in national security, scientific research, space debris mitigation, Earth observation, climate monitoring, and communications. Rocket Lab’s family of spacecraft have been selected to support NASA missions to the Moon and Mars, as well as the first private commercial mission to Venus. Rocket Lab has three launch pads at two launch sites, including two launch pads at a private orbital launch site located in New Zealand and a third launch pad in Virginia. To learn more, visit www.rocketlabusa.com.

+ About Geost

Founded in 2004, Geost, LLC, a LightRidge Solutions Company and portfolio company of ATL Partners, is a rapidly growing producer of affordable high-performance optical systems for critical national security space missions. The company has served its core National Security Space customer base since its founding and employs over 100 high performing professionals. For more information on Geost visit: https://www.geost.com.

+ About ATL Partners:

Founded in 2014, ATL Partners is a premier sector-focused private equity firm that invests in commercial aerospace, national security, and transportation & logistics companies. ATL brings deep sector expertise to its investment approach with experienced investment professionals and strong operating executives who have decades of combined experience in each of ATL’s core sectors. For more information about ATL Partners, visit https://www.atlpartners.com.

+ Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements contained in this press release other than statements of historical fact, including, without limitation, statements regarding the financial and business impact of the transaction and the anticipated benefits of the transaction, our ability to integrate the acquired business with our product and service offerings, our launch and space systems operations, launch schedule and window, safe and repeatable access to space, Neutron development, operational expansion and business strategy are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “potential,” “continue,” “anticipate,” “intend,” “expect,” “strategy,” “future,” “could,” “would,” “project,” “plan,” “target,” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to risks related to the integration of proposed acquisitions, including our ability to achieve the anticipated benefits of the proposed transaction and successfully integrate Geost’s technologies, product offerings and operations, as well as the factors, risks and uncertainties included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as such factors may be updated from time to time in our other filings with the Securities and Exchange Commission (the “SEC”), accessible on the SEC’s website at www.sec.gov and the Investor Relations section of our website at www.rocketlabusa.com, which could cause our actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

Rocket Lab Media Contact

Lindsay McLaurin

[email protected]

KEYWORDS: Virginia California Arizona United States North America

INDUSTRY KEYWORDS: Satellite Air Technology Aerospace Transport Manufacturing Audio/Video

MEDIA:

Photo
Photo
Credit: Rocket Lab
Logo
Logo
Posted on

From Pension Portfolios to Public Markets: Intech’s LGDX ETF Surpasses $100 Million After First 5 Months

38-Year-Old Institutional Strategy, Now Delivering Diversified S&P 500® Exposure Through an ETF

WEST PALM BEACH, Fla., Aug. 12, 2025 (GLOBE NEWSWIRE) — Intech®, a $14 billion institutional equity manager, announced today that its Intech S&P Large Cap Diversified Alpha ETF (NYSE Arca: LGDX) has surpassed $100 million in assets under management after its first five months since launch.

While new to the ETF marketplace, LGDX is powered by a time-tested investment process. For nearly four decades, Intech has managed a diversification-weighted large-cap strategy for pensions, endowments, and sovereign wealth funds. That same process now serves as the foundation for LGDX, offering investors a core U.S. equity allocation with benchmark alignment, institutional rigor, and the potential for better risk-adjusted returns—all in a transparent, tax-efficient ETF.

“LGDX gives advisors and their clients access to a strategy that’s served institutional portfolios for nearly four decades,” said Andre Prawoto, Head of Strategy at Intech. “Crossing the $100 million mark so early reflects confidence in the strategy and establishes a strong foundation for broader platform access and model portfolio inclusion.”

Launched on February 27, 2025, LGDX outperformed the S&P 500 Index in its first full calendar quarter as an ETF, continuing the long-term track record of its predecessor fund, which has been live since March 1, 2004.

TRAILING PERFORMANCE: LGDX VS. S&P 500® INDEX AS OF JUNE 30, 2025
  3 Month 1 Year 3 Year 5 Year 10 Year Inception
(03/01/04)
LGDX (NAV) 11.77 16.15 20.91 17.10 13.41 10.61
LGDX (Market Price) 11.76 16.26 20.94 17.13 13.42 10.61
S&P 500

®

Index 		10.94 14.85 19.69 16.63 13.63 8.80

Gross Expense Ratio: 0.25%

Performance data quoted represents past performance. Past performance does not guarantee future results. Investment return and principal value will fluctuate, so shares may be worth more or less than the original cost when sold. Current performance may be higher or lower than that shown. For the most recent month-end performance, visit https://www.intechetfs.com/lgdx

LGDX performance history before 02/27/2025 reflects the results of the predecessor fund, a commingled private investment vehicle that was not registered under the Investment Company Act of 1940. The predecessor fund was managed using the same strategy and objectives as the ETF; however, it was not subject to the same regulatory, fee, or expense structure, which may have impacted its results. Net asset values (NAVs) of the predecessor fund were used for both NAV and market price performance from inception to the listing date. Performance reflects the deduction of applicable predecessor fund fees and expenses. For periods after 02/27/2025, ETF performance reflects the deduction of all applicable fund expenses, including management fees, trading costs, and other operating expenses. Returns would have been higher if the ETF’s lower expense ratio had been applied historically over time.

LGDX launched alongside SMDX, Intech’s SMID-cap ETF, as part of the firm’s broader effort to bring its institutional strategies to financial advisors and individual investors. Both funds have gained early traction, reflecting advisor demand for systematic approaches with institutional roots—delivered in transparent, tax-efficient vehicles built for long-term portfolio construction.

About Intech

For over 38 years, Intech has been at the forefront of systematic investing, pioneering strategies that harness the power of diversification and rebalancing to optimize equity portfolios. With $14.7 billion in assets under management as of June 30, 2025, Intech’s research-driven approach—trusted by pension funds, endowments, and sovereign wealth funds—is now accessible to all investors through Intech ETFs, offering a new way to think about passive investing in a rapidly evolving market. Learn more at www.intechetfs.com.

Media Contact

Amiee Watts
FLX Networks
[email protected]
1-973-615-1683

Investors should consider the investment objectives, risks, charges and expenses carefully before investing. For a prospectus or summary prospectus with this and other information about the Funds, visit 

www.IntechETFs.com

. Read the prospectus or summary prospectus carefully before investing.

PRINCIPAL RISKS: Investing involves risk, including the possible loss of principal. There is no guarantee the Fund will achieve its investment objective. Because the value of your investment in the Fund will fluctuate, there is a risk that you may lose money. The Funds’ principal risks include equity market risk, volatility risk, and market capitalization risk. Equity Market Risk: Stock prices can fluctuate significantly due to economic, political, and market conditions. The Fund’s investments in equities may experience sudden declines or prolonged downturns. Volatility Risk: The Fund’s strategy leverages stock price volatility to optimize index exposure, but market swings can be unpredictable. High volatility may lead to short-term price fluctuations that could impact performance, particularly during periods of extreme market stress. Market Capitalization Risk: Large-cap stocks may be less volatile but offer slower growth. Small- and mid-cap stocks can experience higher volatility and liquidity risks.

ETFs trade like stocks, fluctuate in value, and may trade at bid-ask spreads or at a premium or discount to NAV, particularly during periods of market stress. Brokerage commissions and fund expenses will reduce returns.

The S&P 500® is an S&P Dow Jones Indices LLC (“SPDJI”) product, licensed for use by Intech. S&P® and S&P 500®, The 500™, US 500™ and other index names are trademarks of S&P Global, used under license. Intech ETFs are not sponsored or sold by SPDJI, S&P Global, or their affiliates, which make no representation regarding investing. Indices are unmanaged, do not reflect fees, and are not available for direct investment.

Intech is the sub-advisor to Intech ETFs. Intech ETFs are distributed by Foreside Fund Services, LLC.

Investment Products: Not FDIC Insured • Not Bank Guaranteed • May Lose Value • Intech does not have any bank affiliates.

A video accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/9b988632-2f56-4ae8-adc1-3222af5e7276



Posted on

IQST – IQSTEL Blew Past Its Goals With $35 Million in July Revenue — Surpasses $400 Million Annual Run Rate Five Months Ahead of Schedule on Path to $1 Billion by 2027

PR Newswire


NEW YORK
, Aug. 12, 2025 /PRNewswire/ — IQSTEL Inc. (NASDAQ: IQST) today announced preliminary July 2025 revenue of approximately $35 million, surpassing the Company’s $400 million annualized revenue run rate — five months ahead of its internal schedule.

If IQSTEL maintains this revenue level through the second half of 2025, the Company projects $210 million in second-half revenue, keeping it firmly on track to achieve its $340 million full-year revenue goal. The current revenue mix is approximately 80% telecom and 20% fintech.

Executing on Growth, Profitability, and Shareholder Value

Over the years, every acquisition IQSTEL has executed has resulted in:

  • Increased revenue per share
  • Increased net shareholders’ equity
  • Increased net shareholders’ equity per issued share

This disciplined value-creation approach remains central to the Company’s strategy. This is how IQSTEL has grown from $13 million in revenue in 2018 to nearly $300 million in 2024, with a clear goal of becoming a $1 billion revenue company by 2027; and from a deficit in the Net Shareholder’s equity of $1.5 million in 2018 to positive Net Shareholder’s Equity of $11.9 million in 2024.

Since its NASDAQ uplisting, IQSTEL has strengthened its financial position by reducing nearly $7 million in debt — the equivalent of approximately $2 per share. This achievement enhances the Company’s balance sheet and expands its capacity for reinvestment, directly supporting long-term shareholder value.

Of this $7 million debt reduction, $3.5 million was converted into preferred shares, reflecting debt holders’ confidence in the Company’s strategic direction and management team. Choosing equity over fixed interest payments demonstrates these stakeholders’ belief in IQSTEL’s long-term growth potential.

The Company is upgrading its accounting systems and workflows to enable monthly reporting of both revenue and EBITDA. Introducing EBITDA per share as a key performance metric — an important tool for measuring the Company’s ability to create shareholder value.

In addition, several institutional investment holdings have recently taken positions in IQSTEL in the open market — a further sign of market confidence. This information is publicly available on Nasdaq’s institutional holdings page:

https://www.nasdaq.com/market-activity/stocks/iqst/institutional-holdings

As previously disclosed, IQSTEL is actively pursuing acquisitions with the potential to add $10 million in EBITDA, aiming for a $15 million EBITDA run rate in operating businesses by 2026. These transactions are expected to take place over the next 18 months, with a disciplined, value-driven approach rather than a rushed timeline.

A Strategic Leap with Cycurion

IQSTEL recently signed a Memorandum of Understanding (MOU) with Cycurion Inc. (NASDAQ: CYCU) — a highly strategic move that will integrate high-tech, high-margin services into IQSTEL’s business platform.

Through this collaboration, IQSTEL and Cycurion will combine expertise to deliver next-generation, AI-driven cybersecurity solutions to telecom operators, governments, and enterprises worldwide. This initiative supports IQSTEL’s goal of becoming not only a large player, but a leader in the industry — with a direct, positive impact on shareholder value.

Building for the Next Decade

IQSTEL continues to prepare for sustained growth well beyond its current planning horizon.

“We think long-term,” said Leandro Iglesias, CEO of IQSTEL. “Our strategies are designed not only to deliver strong results in the coming years but also to ensure IQSTEL is ready to lead our industry into the next decade.”

Why $1 Billion in Revenue Matters

IQSTEL’s strategic target is to reach $1 billion in revenue by 2027. In its sector, public peers with $1 billion in revenue often trade at 10x to 20x EBITDA multiples. Achieving this milestone would help IQSTEL close what it views as a significant valuation gap compared to sector leaders, unlocking substantial shareholder value.

We invite investors to review the Litchfield Hills Research report on IQSTEL, which issued a Buy rating with a price target range of $18–$22.

About IQSTEL Inc.

IQSTEL Inc. (NASDAQ: IQST) is a multinational technology company providing advanced solutions across Telecom, High-Tech Telecom Services, Fintech, AI-Powered Telecom Platforms, and Cybersecurity. With operations in 21 countries and a team of 100 employees, IQSTEL serves a broad global customer base with high-value, high-margin services. Backed by a strong and scalable business platform, the company is forecasting $340 million in revenue for FY-2025, reinforcing its trajectory toward becoming a $1 billion tech-driven enterprise by 2027.

Use of Non-GAAP Financial Measures: The Company uses certain financial calculations such as Adjusted EBITDA, Return on Assets and Return on Equity as factors in the measurement and evaluation of the Company’s operating performance and period-over-period growth. The Company derives these financial calculations on the basis of methodologies other than generally accepted accounting principles (“GAAP”), primarily by excluding from a comparable GAAP measure certain items the Company does not consider to be representative of its actual operating performance. These financial calculations are “non-GAAP financial measures” as defined under the SEC rules. The Company uses these non-GAAP financial measures in operating its business because management believes they are less susceptible to variances in actual operating performance that can result from the excluded items, other infrequent charges and currency fluctuations. The Company presents these financial measures to investors because management believes they are useful to investors in evaluating the primary factors that drive the Company’s core operating performance and provide greater transparency into the Company’s results of operations. However, items that are excluded and other adjustments and assumptions that are made in calculating these non-GAAP financial measures are significant components in understanding and assessing the Company’s financial performance. These non-GAAP financial measures should be evaluated in conjunction with, and are not a substitute for, the Company’s GAAP financial measures. Further, because these non-GAAP financial measures are not determined in accordance with GAAP, and are thus susceptible to varying calculations, the non-GAAP financial measures, as presented, may not be comparable to other similarly-titled measures of other companies.

Adjusted EBITDA is not a recognized accounting measurement under GAAP; it should not be considered as an alternative to net income, as a measure of operating results, or as an alternative to cash flow as a measure of liquidity. It is presented here not as an alternative to net income, but rather as a measure of the Company’s operating performance. Adjusted EBITDA excludes, in addition to non-operational expenses like interest expenses, taxes, depreciation and amortization; items that we believe are not indicative of our operating performance, such as:

  • Change in Fair Value of Derivative Liabilities: These adjustments reflect unrealized gains or losses that are non-operational and subject to market volatility.
  • Loss on Settlement of Debt: This represents non-recurring expenses associated with specific financing activities and does not impact ongoing business operations.
  • Stock-Based Compensation: As a non-cash expense, this adjustment eliminates variability caused by equity-based incentives.

The Company believes Adjusted EBITDA offers a clearer view of the cash-generating potential of its business, excluding non-recurring, non-cash, and non-operational impacts. Management believes that Adjusted EBITDA is useful in evaluating the Company’s operating performance compared to that of other companies in its industry because the calculation of Adjusted EBITDA generally eliminates the effects of financing, income taxes, non-cash and certain other items that may vary for different companies for reasons unrelated to overall operating performance and also believes this information is useful to investors.

Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. Words such as “anticipate,” “believe,” “estimate,” “expect,” “intend”, “could” and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to successfully market our products and services; our continued ability to pay operating costs and ability to meet demand for our products and services; the amount and nature of competition from other telecom products and services; the effects of changes in the cybersecurity and telecom markets; our ability to successfully develop new products and services; our ability to complete complementary acquisitions and dispositions that benefit our company; our success establishing and maintaining collaborative, strategic alliance agreements with our industry partners; our ability to comply with applicable regulations; our ability to secure capital when needed; and the other risks and uncertainties described in our prior filings with the Securities and Exchange Commission.

These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and IQSTEL Inc. undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release.

For more information, please visit www.IQSTEL.com.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/iqst—iqstel-blew-past-its-goals-with-35-million-in-july-revenue–surpasses-400-million-annual-run-rate-five-months-ahead-of-schedule-on-path-to-1-billion-by-2027-302527036.html

SOURCE iQSTEL

Posted on

Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology

PR Newswire

Newly issued patent extends protection of proprietary solid tumor CAR-T platform to 2045


SAN JOSE, Calif.
, Aug. 12, 2025 /PRNewswire/ — Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent Number 12,384,826 covering its chimeric antigen receptor-T cell (CAR-T) technology. This new patent extends protection of Anixa’s CAR-T technology to 2045.

The allowed claims in this patent encompass core methods and compositions that are fundamental to Anixa’s innovative CAR-T approach. Anixa’s CAR-T platform is specifically designed to address the long-standing challenges of applying CAR-T therapies to solid tumors, positioning the program as a potential breakthrough in immuno-oncology. This newly issued patent builds on Anixa’s growing portfolio of CAR-T intellectual property, collectively designed to protect the platform’s use across multiple tumor types. This patent, along with others, was granted to The Wistar Institute and exclusively licensed to Anixa Biosciences. Anixa’s CAR-T technology is currently in a clinical trial at Moffitt Cancer Center, treating recurrent ovarian cancer patients.

Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences, stated, “This issued patent further strengthens our growing intellectual property portfolio and reinforces the potential of our novel CAR-T program. Broadening patent protection is a vital step in supporting the program’s future success, both clinically and commercially.”

About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa’s therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company’s vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against “retired” proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa’s unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on LinkedIn, X, Facebook and YouTube.

Forward-Looking Statements

Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa’s current expectations concerning future events and results. We generally use the words “believes,” “expects,” “intends,” “plans,” “anticipates,” “likely,” “will” and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in “Item 1A – Risk Factors” and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

Contact:

Mike Catelani

President, COO & CFO
[email protected]
408-708-9808

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-announces-issuance-of-additional-us-patent-for-car-t-technology-302527691.html

SOURCE Anixa Biosciences, Inc.

Posted on

AGCO Names New PTx Leader to Accelerate Smart Farming Solutions and Growth

PR Newswire


DULUTH, Ga.
, Aug. 12, 2025 /PRNewswire/ — AGCO (NYSE: AGCO), a global leader in the design, manufacture and distribution of agricultural machinery and precision ag technology, announced the appointment of Brian Sorbe as President of PTx, effective August 25, 2025. With nearly three decades of experience in precision agriculture, global sales and product development, Sorbe brings a wealth of expertise to this pivotal role.

“I am thrilled to welcome Brian to the AGCO team as the leader of our exciting PTx technology portfolio,” said Eric Hansotia, Chairman, President and CEO. “His passion for agriculture and ability to inspire teams will accelerate the momentum building in our entire PTx organization through a focus on retrofit innovation and farmer education. Brian’s extensive commercial and ag tech innovation background, expertise in channel development and successful track record in managing complex technology platforms will serve our people and farmers well. I am confident under Brian’s leadership, PTx will achieve our goal of $2 billion in precision ag sales by 2029 and help us deliver our vision to be the trusted partner for industry-leading, smart farming solutions.”

Sorbe spent 14 years at Topcon Positioning Systems in key leadership roles, including Senior Vice President and General Manager. At Topcon, he led cross-functional teams across many areas including technology development for mixed fleets, product strategy, marketing and M&A integration, consistently driving farmer-focused solutions to market. Sorbe’s career also spans construction and industrial automation, but agriculture has always been at the core. Raised on a farm in Iowa, Sorbe began his precision ag journey at Ag-Chem Equipment in Jackson, Minnesota, now part of AGCO following the 2001 Ag-Chem acquisition.

Sorbe will be based in Tremont, Illinois, which is a key PTx site
. He holds a Bachelor of Business Administration degree from the Purdue University system. Sorbe’s postgraduate work includes certifications in AI & Machine Learning and Agricultural Autonomy & Robotics as well as a Master of Business of Administration program.

Forward Looking Statement

Certain statements in this release are forward-looking, including statements with regard to the future performance and operation of the Company. Actual results could differ materially from those reflected in this release for a range of reasons, including: general economic and capital market conditions; availability of credit to our retail customers; the worldwide demand for agricultural products; grain stock levels and the levels of new and used field inventories; cost of steel and other raw materials; energy costs; performance and collectability of the accounts receivable originated or owned by AGCO or our finance joint ventures; government policies, tariffs and subsidies; uncertainty regarding changes in the international tariff regimes (including implementation of new tariffs and retaliatory measures) and product embargoes and their impact on the cost of the products that we sell; weather conditions; interest and foreign currency exchange rates; limitations on ability to repatriate funds; inflation, including in individual countries that have been designated as highly inflationary; pricing and product actions taken by competitors; commodity prices, acreage planted and crop yields; farm income, land values, debt levels and access to credit; pervasive livestock diseases; production disruptions, including due to component and raw material availability; production levels and capacity constraints at our facilities, including those resulting from plant expansions and systems upgrades; integration of recent and future acquisitions, including the completed acquisition on April 1, 2024 of the Trimble ag assets and formation of the joint venture, PTx Trimble, and the ability to obtain the expected results; our expansion plans in emerging markets; supply constraints, including energy shortages; our cost reduction and control initiatives; our research and development efforts; dealer and distributor actions; regulations affecting privacy and data protection; technological difficulties; the impact of future pandemics on product demand and production; the occurrence of future cyberattacks, including ransomware attacks; the conflict in Ukraine; and restrictive covenants, payment obligations and other factors related to our level of indebtedness. Any forward-looking statement speaks only as of the date on which such statement is made, and we disclaim any obligation to update the information contained in such statement to reflect subsequent developments or information except as required by law.

About AGCO

AGCO (NYSE: AGCO) is a global leader in the design, manufacture and distribution of agricultural machinery and precision ag technology. AGCO delivers value to farmers and OEM customers through its differentiated brand portfolio including leading brands Fendt®, Massey Ferguson®, PTx and Valtra®. AGCO’s full line of equipment, smart farming solutions and services helps farmers sustainably feed our world. Founded in 1990 and headquartered in Duluth, Georgia, USA, AGCO had net sales of approximately $11.7 billion in 2024. For more information, visit www.agcocorp.com.  

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/agco-names-new-ptx-leader-to-accelerate-smart-farming-solutions-and-growth-302526831.html

SOURCE AGCO Corporation

Posted on

Ovivo to Sell its Electronics Division to Ecolab and Start a New Phase of Growth

PR Newswire


MONTREAL
, Aug. 12, 2025 /PRNewswire/ – Ovivo Inc. (“Ovivo”), a global provider of water and wastewater treatment equipment, technology and systems and its shareholder SKion Water GmbH (“SKion Water”), today announce that they have entered into a definitive agreement to sell Ovivo’s Electronics division to Ecolab, a global sustainability leader offering water, hygiene and infection prevention solutions and services. Based in Saint Paul, Minnesota, USA, Ecolab is traded on the New York Stock Exchange and operates in more than 170 countries with 48,000 employees. The transaction has an enterprise valuation of approximately 2.4 billion Canadian dollars and is expected to close in the first quarter of 2026, subject to the parties obtaining regulatory clearance and satisfaction of other customary closing conditions.

This transaction will be a milestone in the history of Ovivo. It will open new perspectives and opportunities for the Electronics division within Ecolab and be the start of a new phase for Ovivo, driving its success further by accelerating progress across its three operational pillars: the Municipal/Industrial/PFAS division, the Energy division and Cembrane SiC membrane division.

“This transaction is a testament to the world leading market position that our Electronics division has built over the last decades. Through teamwork and innovation, a team with unmatched knowledge and capabilities has been created. Becoming part of Ecolab will lay the foundation for the next level of development for the division and its employees. For the Municipal/Industrial/PFAS, Energy and Cembrane divisions, this transition will be the start of a new growth phase,” said Marc Barbeau, President and Chief Executive Officer of Ovivo.

“SKion Water will continue its growth strategy. At Ovivo our focus will be to accelerate organic growth in the Municipal, Energy and Cembrane business and to build out our industrial business in North America through acquisitions. This transition also creates an opportunity for us to strengthen the collaboration across the SKion Water portfolio. In addition, we will bring closer together the corporate functions of SKion Water and Ovivo to leverage our in-house expertise,” says Reinhard Huebner, SKion Water CEO.

Ovivo was advised by McCarthy Tétrault LLP as legal counsel.

About Ovivo Inc.

Ovivo is a global provider of equipment, technology and systems producing among the purest water and treating some of the most challenging wastewater in the industry. Ovivo is a powerful global brand with renowned trademarks, possessing more than 150 years of expertise and references in water treatment, supported by its proprietary products, advanced technologies and extensive system integration knowhow. Ovivo delivers conventional to highly technological water treatment solutions for the industrial and municipal markets and leverages its large installed base of equipment around the world to offer parts and services to its customers. Ovivo is dedicated to innovation in an industry that is in constant evolution and offers water treatment solutions that are cost-effective, energy-efficient and environmentally sustainable.

Ovivo operates an integrated global platform in 18 countries and employs more than 1,500 experts in water treatment across the world. Ovivo is owned by German SKion Water GmbH, a global technology and solution provider as well as plant manufacturer, in both municipal and industrial water and wastewater technology. SKion Water is a subsidiary of the German entrepreneur family Klatten’s investment holding company SKion GmbH.

www.ovivowater.com.

Follow us on LinkedIn @Ovivo and Facebook @Ovivo.

About Ecolab

A trusted partner for millions of customers, Ecolab (NYSE:ECL) is a global sustainability leader offering water, hygiene and infection prevention solutions and services that protect people and the resources vital to life. Building on more than a century of innovation, Ecolab has annual sales of US$16 billion, employs approximately 48,000 associates and operates in more than 170 countries around the world. The company delivers comprehensive science-based solutions, data-driven insights and world-class service to advance food safety, maintain clean and safe environments, and optimize water and energy use. Ecolab’s innovative solutions improve operational efficiencies and sustainability for customers in the food, healthcare, high tech, life sciences, hospitality and industrial markets.

www.ecolab.com

Follow us on LinkedIn @Ecolab, Instagram @Ecolab_Inc and Facebook @Ecolab.

Cision View original content:https://www.prnewswire.com/news-releases/ovivo-to-sell-its-electronics-division-to-ecolab-and-start-a-new-phase-of-growth-302527454.html

SOURCE Ovivo Inc.

Posted on

This Restored 1999 Defender 110 with an LT1 and French Oak Evokes ‘Old English’

KISSIMMEE, Fla., Aug. 12, 2025 (GLOBE NEWSWIRE) — ECD Automotive Design, the world’s leader in reimagined Land Rovers, proudly introduces Project Pearl, a stunning custom-built Defender 110 Signature that merges timeless British heritage with modern American performance and comfort. Clad in Old English White and finished with painstaking detail from roof to undercarriage, Project Pearl is a fully bespoke expression of refined adventure.


Images
 of Project Pearl


Video
 of Project Pearl

Under the hood lies a GM LT1 V8 engine pushing 455 horsepower, paired with a 10-speed automatic transmission and custom Lokar shifter. With Alcon high-performance brakes, ECD’s signature air suspension, and a sport dual exhaust system, Project Pearl delivers effortless power, ultra-smooth road handling, and a growl worthy of its stature.

But where Project Pearl truly shines is in its visual and tactile storytelling. From the fully body-colored roll cage, ladder, bumpers, and custom open front storage rack, to the French Oak wood inserts in the rear bumper step and cargo area, every inch of this build radiates sophistication. Bathed in natural light, Project Pearl’s panoramic twin moon roofs stretch wide above the cabin interior, turning every drive into an open-air escape. The front sunroof glides open to welcome in cool breezes, letting the scent of the road and the rhythm of the wind flow through. Whether cruising coastal highways or winding through the countryside, the glass expanse blurs the line between inside and out, making each journey feel boundless. Pearl’s cabin is luxury wrapped in Porsche Nappa Cream leather, custom wood-trimmed consoles, and hydro-dipped orange wood grain finishes that echo fine furniture craftsmanship more than traditional automotive design.

“Project Pearl is a masterclass in legacy, performance, and individuality,” said Elliot Humble, Co-Founder of ECD. “Our process is built on understanding and translating our clients’ distinct desires into tangible results. When coupled with the deep expertise and refined craftsmanship of our production team, the outcome is something truly special and personalized.”

Designed for its owners who reside in Washington State, Project Pearl is a statement piece. From the 20-inch Kahn Retro Mondial wheels to the custom silver metal hardware, and the rear swing-out spare carrier, this D110 is ready to turn heads from city streets to coastal highways.

Project Pearl also integrates cutting-edge creature comforts, including wireless CarPlay, heated seats, Bluetooth audio, blind spot assistance, and a digital rearview mirror. It’s every bit a luxury daily driver, wrapped in the soul of a rugged icon.

As with every ECD build, Project Pearl is handcrafted, down to the last stitch of German square weave carpet and the satin finish on its wood grain accents.

Project Pearl Specifications

Model — Land Rover Defender 110 – Signature
Engine — LT1 – GM V8 / 455 HP
Transmission — 10 Speed Automatic
Brakes — ALCON – High Performance
Suspension — ECD Air Ride
Exhaust — Sport Dual Plus – Twin Outlets Left & Right
Exterior Color — Old English White
Wheels — 20 Inch Kahn Retro Mondial – Painted Zermatt Silver
Tires — BFG All Terrain – Black Walls Out
Side Steps — Black with Silver Inserts / Tube Painted in Body Color
Roll Cage — Full External / 6 Point – Painted in Body Color
Roof — Double panoramic + sunroof
Seat Layout — 2 + 2 + 4
Dash — Puma wrapped in approved leather
Seats — Corbeau Sport
Leather — Porsche Nappa Cream leather
Stitch Style — Wide Horizontal Stitch Bars on Middle Inserts
Custom features — Wood Panels in Cargo Area Flooring – French Oak Stain / Satin Finish. Picture Frame Style Casing with White Caulking. Wooden Inserts for NAS rear step – Matching interior wood, Rear Gate Leaver Cover in French Oak Wood, Satin Finish
Gauges — Classic White
Carpet — RELICATE – German Square Weave – 400 Tan
Radio — Touch screen stereo with CarPlay
Subwoofer — Active Subs
Rear AC — Yes
Additional features — Cameras Back-up, power windows, central locking, remote locking and Alarm, remote start, Blind Spot Assistant

About ECD Automotive Design

ECD, a public company trading under ECDA on the Nasdaq, is a creator of restored luxury vehicles that combines classic beauty with modern performance. Currently, ECD restores Land Rovers Series, Land Rover Series IIA, the Range Rover Classic, Jaguar E-Type, Ford Mustang, Toyota FJ, and highly specialized vehicles from its Boutique Studio. Each vehicle produced by ECD is fully bespoke, a one-off that is designed by the client through an immersive luxury design experience and hand-built from the ground up in 2,200 hours by master-certified Automotive Service Excellence (“ASE”) craftsmen. The company was founded in 2013 by three British “gear heads” whose passion for classic vehicles is the driving force behind exceptionally high standards for quality, custom luxury vehicles. ECD’s global headquarters is a 100,000-square-foot facility located in Kissimmee, Florida that is home to 105 talented and dedicated employees that hold combined 80 ASE and five master level certifications. ECD has an affiliated logistics center in the U.K. where its seven employees work to source and transport 25-year-old work vehicles back to the U.S. for restoration. For more information, visit www.ecdautodesign.com.

Media Inquiries:

Dia Stewart
[email protected]
(407) 483-4825

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/447055e6-0871-433d-a353-086e586fdc33



Posted on

Talkspace Adopts Express Access—an AI-Powered Referral Infrastructure to Help PCPs and Employers Deliver Personalized Mental Health Care Faster Than Ever

NEW YORK and BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) — Talkspace, a leading virtual behavioral health provider, and Express Access, the National Institutes of Health funded referral platform developed by Outcome Referrals, today announced a new partnership that will reshape how Americans access mental health care.

Talkspace is the first national digital provider to fully adopt the Express Access TOP Match™ system at scale—integrating scientific provider matching and real-time patient progress tracking directly into its care model. Patients can now get Express Access through their employer or by scanning a free QR code offered by their primary care physician—instantly connecting them to matched Talkspace providers with the best record of helping people like them get better.

Patients can book an appointment with a TOP Matched provider in less time than most patients wait on hold calling a random provider from an insurance directory. As a Cornerstone TOP Match Innovator™, Talkspace will embed the Treatment Outcome Package (TOP) as its core outcome-informed care platform. This robust, 360-degree diagnostic and monitoring system powers Express Access’s AI-enabled decision support tools, identifying clinicians with exceptional track records of success for each patient’s specific needs.

In Patient-Centered Outcomes Research Institute (PCORI) funded and Journal of the American Medical Association published results, the TOP Match system has been shown to quintuple recovery rates, reduce relapse, and consistently identify the providers most likely to help patients return to full health.

“Matching the right providers with the core patient needs has always been the center of driving Talkspace outcomes, and this partnership extends our foundational research that the right provider to right patient drives the best outcomes,” said Erin Boyd, chief growth officer of Talkspace. “Express Access brings a new level of science and transparency to referrals that the behavioral health system has never had—and Talkspace is proud to lead that transformation.”

Solving the Behavioral Health Referral Crisis with Science

Each year, more than 28 million Americans seek help for mental health concerns. Yet many never receive effective care due to long waitlists, mismatched providers, and confusing referral processes. Primary care physicians (PCPs)—often the first point of contact—are overwhelmed and under-equipped.

Express Access changes that. Built with over $30 million in federal and foundation grants and proven in one of PCORI’s most successful comparative effectiveness trials, the platform enables patients to be matched with clinicians whose proven, recent-past outcomes align with their needs—making personalized medicine a reality for millions of Americans in need.

“Until now, healthcare had two pillars: diagnosis and treatment,” said David Kraus, PhD, founder of Express Access. “We’ve proven that the referral itself can—and must—be scientific. With Talkspace on board, we can bring that science to every corner of the country—digitally and equitably. There’s no more guessing, Googling, or praying someone calls back. With Express Access, the best care finds you.”

National Reach, Immediate Access, Higher Quality

Talkspace’s national network of nearly 6,000 clinicians and widespread insurance coverage makes them a uniquely positioned partner to scale Express Access nationwide. With shared goals of reducing no-shows, increasing treatment completion, and unlocking value-based contracts with health plans, this partnership redefines what patients and payers should expect from digital mental health.

About Talkspace

Talkspace (NASDAQ: TALK) is a leading virtual behavioral healthcare company that connects individuals and licensed therapists through secure, affordable, and evidence-based care. Talkspace serves individuals, employers, and health plans across the country.

About Express Access

Express Access is a smart referral infrastructure for behavioral health, developed by Outcome Referrals, Inc., and funded in part by the National Institutes of Health. It uses AI and the Treatment Outcome Package (TOP) to scientifically match patients to behavioral health providers based on real-world outcomes. Express Access is a free benefit for members of the American Academy of Family Physicians (AAFP) and other clinical networks. Outcome Referrals’ mission is to make behavioral health work for everyone—by making outcomes transparent, measurable, and actionable.



Media Contact:
Cary Conway
[email protected]

Posted on

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Aris Water Solutions, Inc. (NYSE – ARIS), American Woodmark Corporation (Nasdaq – AMWD), Performant Healthcare, Inc. (Nasdaq – PHLT), DallasNews Corporation (Nasdaq – DALN)

BALA CYNWYD, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) — Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.

Aris Water Solutions, Inc. (NYSE – ARIS)

Under the terms of the agreement, Aris will be acquired by Western Midstream Partners, LP (“WES”) (NYSE – WES). Aris shareholders will receive 0.625 common units of WES for each Aris share, with the option to elect to receive $25.00 per share in cash. The total enterprise value of the transaction is approximately $2.0 billion before transaction costs. The investigation concerns whether the Aris Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company’s shareholders.

Additional information can be found at https://www.brodskysmith.com/cases/aris-water-solutions-inc-nyse-aris/.

American Woodmark Corporation (Nasdaq – AMWD)

Under the terms of the Merger Agreement, American Woodwork will be acquired by MasterBrand, Inc. (“MasterBrand”) (NYSE – MBC). American Woodmark shareholders will receive 5.150 shares of MasterBrand common stock for each share of American Woodmark common stock owned. MasterBrand and American Woodmark shareholders will own approximately 63% and 37% of the combined company, respectively. The investigation concerns whether the American Woodmark Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company’s shareholders.

Additional information can be found at https://www.brodskysmith.com/cases/american-woodmark-corporation-nasdaq-amwd/.

DallasNews Corporation (Nasdaq – DALN)

Under the terms of the Merger Agreement, DallasNews will be acquired by Hearst for $14.00 per share in cash. The investigation concerns whether the DallasNews Therapeutics Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company’s shareholders.

Additional information can be found at https://www.brodskysmith.com/cases/dallasnews-corporation-nasdaq-daln/.

Performant Healthcare, Inc. (Nasdaq – PHLT)

Under the terms of the Merger Agreement, Performant Healthcare will be acquired by Machinify for $7.75 per share in cash. The investigation concerns whether the Performant Healthcare Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the consideration provides fair value to the Company’s shareholders.

Additional information can be found at https://www.brodskysmith.com/cases/performant-healthcare-inc-nasdaq-phlt/.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.



Posted on

Ginkgo Automation Appoints Brian O’Sullivan as Head of Commercial to Accelerate External Growth

PR Newswire

Seasoned life‑science executive to spearhead global go‑to‑market strategy as Ginkgo Automation scales external sales across biopharma, techbio, and new science‑driven markets while continuing to support internal programs.


BOSTON
, Aug. 12, 2025 /PRNewswire/ — Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the appointment of Brian O’Sullivan as Head of Commercial for Ginkgo Automation. Brian joins Ginkgo Automation from HighRes Biosolutions, where he led their commercial efforts.

In his new role, Brian will oversee all revenue‑generating functions, including sales, business development, channel partnerships, marketing, and customer success, at a pivotal moment for Ginkgo Automation. Over the past year, the business unit has quickly evolved from supporting Ginkgo’s internal R&D to providing its modular RAC (Reconfigurable Automation Cart) hardware, Catalyst scheduling and orchestration software, and remote monitoring and error resolution services to external clients. Ginkgo Automation now serves a rapidly expanding customer base across biopharma, diagnostics, and national laboratories.

“Brian has consistently built top-performing commercial teams that translate advanced technology into clear customer value,” said Will Serber, GM, Ginkgo Automation. “His expertise in developing and executing capex and software solutions, executing large automation transactions, and his robust network across the life sciences market uniquely positions us to scale globally and maximize the power of our platform.”

At HighRes, Brian built the commercial organization from the ground up, dramatically grew annual bookings, established key strategic alliances across leading industry segments, and spearheaded the company’s expansion into Europe and Asia Pacific. Prior to HighRes, he held senior commercial leadership roles at Agilent Technologies, Velocity11, and Beckman Coulter advancing growth across small molecule and biologic applications. Brian received his Bachelor of Science in Biochemistry from California Polytechnic State University, San Luis Obispo.

“Ginkgo Automation pairs best‑in‑class hardware in a novel design with an AI‑ready software stack that closes the loop between experiment design and data generation – exactly what scientists need to accelerate discovery,” said Brian O’Sullivan. “I’m thrilled to join this talented team and empower customers to reimagine what’s possible in their labs.”

Brian will be based in Emeryville, CA and report directly to Will Serber. His immediate priorities include expanding Ginkgo Automation’s commercial reach, strengthening relationships with enterprise clients, and accelerating market adoption of its innovative solutions.

Ginkgo Automation capabilities can now be deployed at your site. Find out more about our RACs and Catalyst automation software here or at automation.ginkgo.bio

GINKGO BIOWORKS INVESTOR CONTACT:
[email protected]

GINKGO BIOWORKS MEDIA CONTACT:
[email protected]

About Ginkgo Bioworks
Ginkgo Bioworks builds the tools that make biology easier to engineer for everyone.  Ginkgo R&D Solutions delivers customizable R&D packages—such as protein engineering, nucleic acid design, and cell-free systems—giving partners a comprehensive way to accelerate innovation across therapeutics, diagnostics, & manufacturing. Ginkgo Automation sells modular, integrated laboratory automation so scientists can spend their days planning and analyzing experiments rather than pipetting in the lab.  Ginkgo Datapoints uses Ginkgo’s in-house automation to generate the large lab data sets to power your AI models.  Ginkgo Biosecurity is building and deploying the next-generation infrastructure and technologies that global leaders need to predict, detect, and respond to a wide variety of biological threats. For more information, visit ginkgobioworks.com and ginkgobiosecurity.com, read our blog, or follow us on social media channels such as X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn.

Forward-Looking Statements of Ginkgo Bioworks
This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the capabilities and potential success of Ginkgo’s cell programming platform. These forward-looking statements generally are identified by the words “believe,” “can,” “project,” “potential,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to realize near-term and long-term cost savings associated with our site consolidation plans, including the ability to terminate leases or find sub-lease tenants for unused facilities, (ii) volatility in the price of Ginkgo’s securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo’s business, (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, including with respect to our solutions and tools offerings, (iv) the risk of downturns in demand for products using synthetic biology, (v) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vi) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vii) the outcome of any pending or potential legal proceedings against Ginkgo, (viii) our ability to realize the expected benefits from and the success of our Foundry platform programs and Codebase assets, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, (x) the product development, production or manufacturing success of our customers, (xi) our exposure to the volatility and liquidity risks inherent in holding equity interests in other operating companies and other non-cash consideration we may receive for our services, (xii) the potential negative impact on our business of our restructuring or the failure to realize the anticipated savings associated therewith and (xiii) the uncertainty regarding government budgetary priorities and funding allocated to government agencies. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Ginkgo’s annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 25, 2025 and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.

GINKGO BIOWORKS INVESTOR CONTACT:
[email protected]

GINKGO BIOWORKS MEDIA CONTACT:
[email protected]

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-automation-appoints-brian-osullivan-as-head-of-commercial-to-accelerate-external-growth-302527500.html

SOURCE Ginkgo Bioworks